argenx SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARGNF research report →
About the company
argenx SE operates as a biotechnology firm, specializing in the advancement of various therapeutic solutions for autoimmune diseases across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's flagship investigational therapy is efgartigimod, currently undergoing Phase III clinical trials for conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Efgartigimod is also in Phase II/III studies for bullous pemphigoid and idiopathic inflammatory myopathy, with a subcutaneous formulation (ENHANZE SC) in preclinical development.
- CEO
- Timothy Van Hauwermeiren
- IPO
- 2015
- Employees
- 1,599
- HQ
- Breda, NL
Price Chart
- Market Cap
- $57.88B
- P/E
- 51.71
- P/S
- 17.41
- P/B
- 7.97
- EV/EBITDA
- 52.22
- Div Yield
- 0.00%
- Gross Margin
- 89.00%
- Op Margin
- 25.64%
- Net Margin
- 33.42%
- ROE
- 16.82%
- ROIC
- 11.74%
- Revenue
- $4.32B · 92.17%
- Net Income
- $1.34B · 61.41%
- EPS
- $21.94 · 57.61%
- Op Income
- $1.03B
- FCF YoY
- 1136.04%
- 52W High
- $960.58
- 52W Low
- $547.60
- 50D MA
- $835.68
- 200D MA
- $827.05
- Beta
- -0.02
- Avg Volume
- 13
Get TickerSpark's AI analysis on ARGNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ARGNF coverage
Recent articles, reports, and earnings notes.
No research on ARGNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARGNF report →Similar companies
Peers in the same neighborhood.